Milnacipran modified-release - Collegium Pharmaceutical

Drug Profile

Milnacipran modified-release - Collegium Pharmaceutical

Alternative Names: COL-007

Latest Information Update: 20 Mar 2014

Price : $50

At a glance

  • Originator Collegium Pharmaceutical; Cypress Bioscience
  • Developer Collegium Pharmaceutical
  • Class Amides; Amines; Analgesics; Antidepressants; Cyclopropanes; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Fibromyalgia

Most Recent Events

  • 20 Mar 2014 Discontinued for Fibromyalgia in USA (PO)
  • 01 Apr 2010 Collegium Pharmaceutical's modified-release milnacipran is available for licensing (http://www.collegiumpharma.com)
  • 01 Apr 2010 Investigation in Fibromyalgia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top